143B Xenograft Model Overview

The 143B xenograft model is derived from a human osteosarcoma cell line, 143B, which was established from a metastatic lesion in the femur of a patient with osteosarcoma. Osteosarcoma is a highly aggressive form of bone cancer that primarily affects children and adolescents. It is often characterized by rapid tumor growth, frequent metastasis to the lungs, and resistance to conventional chemotherapy treatments. The 143B xenograft model is particularly valuable for studying the biology of osteosarcoma, its metastatic behavior, and the mechanisms behind chemotherapy resistance. This model is widely used to evaluate the efficacy of chemotherapy agents, targeted therapies, and immunotherapies aimed at improving treatment outcomes for osteosarcoma patients.

Request a Custom Quote for 143B Xenograft Model

Biological and Molecular Characteristics

143B cells are characterized by their mesenchymal origin and ability to produce osteoid, a bone-like matrix, which is a hallmark of osteosarcoma. These cells harbor various genetic alterations, including mutations in the TP53 tumor suppressor gene, which is commonly found in osteosarcoma and contributes to resistance to apoptosis and uncontrolled cell proliferation. Additionally, 143B cells exhibit dysregulated signaling pathways such as PI3K/AKT and MAPK/ERK, which promote cell survival, proliferation, and metastasis. The model also expresses high levels of matrix metalloproteinases (MMPs), enzymes that facilitate tumor invasion and metastasis. These molecular features make the 143B xenograft model particularly useful for studying the mechanisms of tumor metastasis, testing new therapies, and evaluating resistance to standard chemotherapy agents such as methotrexate and doxorubicin.

Marker	Expression Level	Function
Osteoid	High	Bone matrix produced by tumor cells
TP53	Mutated	Tumor suppressor gene involved in apoptosis
MMPs	High	Involved in tumor invasion and metastasis
PI3K/AKT pathway	Dysregulated	Promotes cell survival and proliferation

In Vivo Model Development and Tumorigenicity

The 143B xenograft model is typically established by implanting 143B cells into immunocompromised mice, such as NOD/SCID or NSG mice. Upon implantation, the cells form solid tumors that replicate the clinical features of osteosarcoma, including high cellularity, production of osteoid, and significant vascularization. The model is particularly valuable for studying the effects of chemotherapy agents such as methotrexate, doxorubicin, and cisplatin, which are standard treatments for osteosarcoma. Given the model’s ability to develop resistance to chemotherapy over time, it provides an excellent system for studying the molecular mechanisms of drug resistance and for testing new agents that aim to overcome these challenges.

In addition to subcutaneous implantation, orthotopic models of 143B can be established by implanting cells directly into the bone of immunocompromised mice. This orthotopic model more accurately mimics the natural growth and invasion of osteosarcoma, allowing for the study of local invasion, metastatic spread to distant organs (particularly the lungs), and the effects of treatment on the tumor microenvironment. The ability of 143B tumors to replicate the bone involvement and metastasis seen in human osteosarcoma makes it an ideal model for studying metastatic disease and evaluating therapies aimed at preventing or treating metastasis.

Request a Custom Quote for 143B Xenograft Model

Histopathology and Immunohistochemical Profile

Histopathological analysis of 143B xenografts reveals the characteristic features of osteosarcoma, including the production of osteoid and malignant cells with abundant cytoplasm, irregular nuclear morphology, and high mitotic activity. The tumors exhibit a combination of solid and cystic growth patterns, with areas of necrosis. Immunohistochemical staining of 143B xenografts shows strong expression of osteoid, confirming the bone matrix production characteristic of osteosarcoma. Additionally, the tumors show high levels of MMPs, which are involved in tumor invasion and metastasis. Elevated levels of phosphorylated AKT are detected, indicating the activation of the PI3K/AKT signaling pathway, which plays a critical role in tumor survival and growth. The tumors also exhibit significant vascularization, as assessed by CD31 staining, highlighting the importance of angiogenesis in supporting tumor growth.

Preclinical Applications and Drug Response

The 143B xenograft model is widely used to evaluate the efficacy of various therapeutic agents for osteosarcoma. The model is particularly useful for testing chemotherapy agents such as methotrexate, doxorubicin, and cisplatin, which are commonly used in the treatment of osteosarcoma. Given the model’s potential for developing resistance to chemotherapy, it is highly useful for investigating chemotherapy resistance mechanisms and testing new drugs that aim to overcome these challenges. The model is also valuable for evaluating targeted therapies that inhibit key signaling pathways involved in tumor progression, such as the PI3K/AKT and MAPK/ERK pathways.

In addition to chemotherapy and targeted therapies, the 143B xenograft model is increasingly used to evaluate the potential of immunotherapies, including immune checkpoint inhibitors, which have shown promise in treating other cancers and are now being explored for osteosarcoma. The ability of 143B cells to metastasize to the lungs provides an excellent platform for testing therapies that target metastatic disease. Furthermore, the model’s ability to replicate key features of osteosarcoma, including bone matrix production and resistance to therapy, makes it an ideal system for investigating combination therapies that include chemotherapy and novel targeted agents.

Request This Model

To request the 143B xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.

Request a Custom Quote for 143B Xenograft Model